REG - PureTech Health PLC - Transaction in Own Shares

Puretech HealthAnnouncement

15/11/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231115:nRSO4530Ta&default-theme=true

RNS Number : 4530T  PureTech Health PLC  15 November 2023

15 November 2023

 

PureTech Health plc

 

Transaction in Own Shares

 

PureTech Health PLC (the "Company") announces that it has purchased the
following number of its ordinary shares of one pence each through Jefferies
International Limited ("Jefferies"), as part of its Share Buyback Programme,
details of which were announced on 9 May 2022.

 

 Date of purchase:                              14 November 2023

 Number of ordinary shares purchased:           2,116

 Highest price paid per share:                  174.00p

 Lowest price paid per share:                   173.20p

 Volume weighted average price paid per share:  173.39p

 

PureTech intends to retain the purchased shares in treasury.

Following the above transaction, the Company will have 16,285,859 ordinary
shares in treasury and has 273,182,300 ordinary shares in issue (excluding
treasury shares). The total number of voting rights in the Company is
therefore 273,182,300 which may be used by shareholders in their calculations
to determine if they are required to notify their interest in, or a change to
their interest in, PureTech Health plc under the FCA's Disclosure Guidance and
Transparency Rules.

 

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (as
incorporated into UK domestic law by the European Union (Withdrawal) Act 2018)
(the Market Abuse Regulation), detailed information about the individual
purchases is available below.

 

About PureTech Health

PureTech is a clinical-stage biotherapeutics company dedicated to giving life
to new classes of medicine to change the lives of patients with devastating
diseases. The Company has created a broad and deep pipeline through its
experienced research and development team and its extensive network of
scientists, clinicians and industry leaders that is being advanced both
internally and through its Founded Entities. PureTech's R&D engine has
resulted in the development of 27 therapeutics and therapeutic candidates,
including two (Plenity® and EndeavorRx®) that have received both U.S.
FDA clearance and European marketing authorization and a third (KarXT) that
has been filed for FDA approval. A number of these programs are being advanced
by PureTech or its Founded Entities in various indications and stages of
clinical development, including registration enabling studies. All of the
underlying programs and platforms that resulted in this pipeline of
therapeutic candidates were initially identified or discovered and then
advanced by the PureTech team through key validation points.

 

For more information, visit www.puretechhealth.com
(http://www.puretechhealth.com/)  or connect with us on X, formerly known as
Twitter, @puretechh.

 

Contact:

PureTech

Investor Relations

IR@puretechhealth.com

Individual Transactions

 

 Transaction Date  Transaction Time  Volume  Price (GBp)  Platform  Transaction Reference Number
 14/11/2023        08:09:59          40      173.2        XLON      00378182799TRLO0.1.1
 14/11/2023        08:10:09          482     173.2        CHIX      00378182809TRLO0.1.1
 14/11/2023        08:10:42          462     173.2        XLON      00378182867TRLO0.1.1
 14/11/2023        08:10:42          612     173.2        BATE      00378182868TRLO0.1.1
 14/11/2023        08:10:42          20      173.2        CHIX      00378182869TRLO0.1.1
 14/11/2023        10:17:59          500     174          CHIX      00378196528TRLO0.1.1

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  POSFLFSDLSLSLIV